MacroGenics and Merck to study margetuximab and pembrolizumb in gastric cancer
22 October 2015 | By Victoria White
Trial startup activities are underway and MacroGenics expects to begin enrolling patients by the first quarter of 2016...
List view / Grid view
News
New UV-Vis Spectrophotometer simplifies sample quality decisions
Life scientists who work with DNA, RNA and proteins can make educated decisions about sample suitability in experiments using a standalone, microvolume spectrophotometer for accurate quantitation and purity measurements to ensure downstream application success.
Gilead’s GS-5734 given to UK Ebola patient
22 October 2015 | By Victoria White
GS-5734 was discovered as part of Gilead’s programme to screen compounds in its libraries for activity against a range of potential emerging viruses, including Ebola...
Piramal’s Vivek Sharma wins CEO of the Year at CPhI Pharma Awards
22 October 2015 | By Victoria White
The CPhI Pharma Awards recognise life sciences firms that turn inspiration into innovation, and celebrate thinkers and creators that are breaking new ground in formulation, process development, packaging, technology, and more...
AstraZeneca and Lilly expand immuno-oncology collaboration
22 October 2015 | By Victoria White
Under the terms of the expanded agreement, AstraZeneca and Lilly will evaluate the safety and efficacy of a range of additional combinations across the companies’ portfolios...
Gene test could predict spread of breast cancer to the brain
21 October 2015 | By Victoria White
Research has found that women whose breast cancer had begun to spread and who tested positive in the αB-crystallin test were three times more likely to have disease that spread to the brain...
NICE recommends ezetimibe for hypercholesterolaemia
21 October 2015 | By Victoria White
The new draft guidance is different to the original 2007 guidance because it reflects the fact that current clinical practice has a greater emphasis on managing CVD risk rather than meeting target cholesterol levels...
FDA approves Coagadex for hereditary Factor X deficiency
21 October 2015 | By Victoria White
Until this orphan drug approval, no specific coagulation factor replacement therapy was available in the US for patients with hereditary Factor X deficiency...
Biogen reports top-line results of natalizumab SPMS study
21 October 2015 | By Victoria White
The Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis did not achieve its primary and secondary endpoints...
Positive head-to-head results for GSK’s umeclidinium in COPD
21 October 2015 | By Victoria White
The results come from two head-to-head studies directly comparing the efficacy and safety of umeclidinium to two available bronchodilator treatments...
Novartis expands its cancer immunotherapy portfolio
21 October 2015 | By Victoria White
Novartis is broadening its portfolio of cancer immunotherapies through the acquisition of Admune Therapeutics and licensing agreements with Palobiofarma and XOMA Corporation...
UNESCO-Merck Africa Research Summit commences
20 October 2015 | By Victoria White
The 2015 UNESCO-Merck Africa Research Summit will focus on the role of building capacities in the life sciences to address challenges of infectious diseases, most notably the Ebola crises...
AstraZeneca opens new manufacturing facility in Russia
20 October 2015 | By Victoria White
Commercial production will begin at the new state-of-the-art site early next year and will focus on final-stage manufacturing, packaging and quality control...
Asia-Pacific multiple myeloma treatment market value to hit $2.8b by 2021
20 October 2015 | By Victoria White
The treatment market for multiple myeloma across China, India, Japan, and Australia will rise in value from $1.7 billion in 2014 to $2.8 billion by 2021...
Stelara induces clinical remission in Crohn’s disease in Phase 3 trial
20 October 2015 | By Victoria White
New Phase 3 data show treatment with Janssen’s Stelara (ustekinumab) induced clinical response and clinical remission in patients with moderate to severe Crohn's disease who had previously failed conventional therapy.
